Investors Overview
Overview
Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.
Minimum 15 minutes delayed. Source:
News Releases
10
Oct '24
25
Sep '24
26
Aug '24
15
Aug '24
Recent Events
November 14, 2024 at 8:00 AM EST
September 5, 2024 at 5:35 PM EDT
August 16, 2024 at 8:00 AM EDT